Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

Art Hogan, chief market strategist at B. Riley Wealth, joins BNN Bloomberg to discuss the outlook on the markets and provide ...

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...

Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

Discover why a 2026 recession may trigger an AI bubble burst, impacting tech stocks, and learn why health care could ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

The post Global Equities Retreat on Tech Weakness, Persistent Inflation, and Slowing UK Growth: Market Analysis for December ...

US stocks retreated on Thursday as investors reassessed the strength of the technology sector. Oracle’s earnings report raised new concerns about the pace of AI ...

The Dow Jones Industrial Average climbed to another record on Friday as investors continued to rotate out of technology ...

In November, Mounjaro clocked Rs 108 crore in sales, making it the number 1 brand in the IPM, reflecting sustained momentum ...